**Core Concept**
6-mercaptopurine (6-MP) is a purine analog used in the treatment of acute lymphoblastic leukemia (ALL) and certain autoimmune diseases. It acts as a competitive inhibitor of xanthine oxidase, an enzyme that metabolizes hypoxanthine and xanthine to uric acid.

**Why the Correct Answer is Right**
6-MP is metabolized to its active form, 6-thioguanine nucleotides (6-TGNs), which are incorporated into DNA, leading to cytotoxicity in rapidly dividing cells. The conversion of 6-MP to 6-TGNs is facilitated by xanthine oxidase inhibition. Additionally, 6-MP is also a substrate for thiopurine methyltransferase (TPMT), an enzyme that inactivates the drug.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because 6-MP is not a prodrug that requires conversion to its active form. Instead, it is already active and exerts its effects directly.
**Option B:** This option is incorrect because 6-MP is not primarily used for its immunosuppressive properties. While it does have some immunosuppressive effects, its primary use is in the treatment of ALL and other hematologic malignancies.
**Option C:** This option is incorrect because 6-MP is actually metabolized by xanthine oxidase, not inhibited by it. Xanthine oxidase is an enzyme that metabolizes hypoxanthine and xanthine to uric acid, and 6-MP is a substrate for this enzyme.

**Clinical Pearl / High-Yield Fact**
It's essential to monitor TPMT levels in patients receiving 6-MP, as TPMT deficiency can lead to increased toxicity and adverse effects.

**Correct Answer: A. 6-MP is not a prodrug that requires conversion to its active form.**